Hikma Pharmaceuticals PLC reiterated earnings guidance for the year 2024. For the year, expected Group revenue to grow in the range of 4% to 6% and for core operating profit to be in the range of $660 million to $700 million in 2024, in line with prior guidance.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,973 GBX | -0.25% | -1.94% | +10.29% |
May. 17 | HIKMA PHARMACEUTICALS : Time to capitalise on Hikma’s ongoing (share price) momentum | |
May. 03 | Deutsche Bank Starts Hikma Pharmaceuticals Coverage at Buy | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+10.29% | 5.58B | |
+34.35% | 693B | |
+29.39% | 584B | |
-3.49% | 372B | |
+20.15% | 332B | |
+6.19% | 294B | |
+14.11% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+9.21% | 168B |
- Stock Market
- Equities
- HIK Stock
- News Hikma Pharmaceuticals PLC
- Hikma Pharmaceuticals plc Reiterates Earnings Guidance for the Year 2024